Clinical trials: Sclerosis, Multiple
Ichthyosis, Palmoplantar Keratoses
Reproductive Options in Inherited Skin Diseases
The goal of this observational study is to learn about the indications for prenatal diagnostics and preimplantation genetic testing for patients/couples affected by an inherited skin disease, and evaluate the clinical outcomes of…
- Conditions
- Ichthyosis, Palmoplantar Keratoses, Epidermolysis Bullosa, Ectodermal Dysplasia
- Trial name
- REPRO-ISD (NCT06330324)
- Where
- Netherlands
- Volunteers
- 650 people
- Sponsor
- Maastricht University Medical Center
Scleroderma, Systemic
Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
This randomized, double-blind, placebo-controlled multi-center study will carry out to assess the efficacy of GB-0998 in the treatment of the systemic sclerosis based on the changes in modified Rodnan total skin thickness score…
- Trial name
- NCT00348296
- Testing
- High-dose intravenous immunoglobulin (Venoglobulin-IH)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Benesis Corporation
Multiple Sclerosis
Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis
Fatigue is one of the most common symptoms, experienced by between 50% and 100% of people with multiple sclerosis (MS), and contributes significantly to the consequences of MS and perceived disability in the daily lives of those…
- Trial name
- HCB_MS (NCT07028879)
- Testing
- Fatigue management program
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Hospital Clinic of Barcelona
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sleep Disorder
Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC)
The proposed research project is aimed at further characterization of sleep problems and evaluation of their impact in children and adults with TSC, excluding epilepsy as contributing factor.
- Trial name
- NCT03326765
- Testing
- Questionnaires, electroencephalogram (EEG), polysomnography
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Relapsing-Remitting Multiple Sclerosis
PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
The primary objective of the study is to determine the pharmacokinetic (PK) profile of multiple doses of natalizumab in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01884935
- Testing
- Natalizumab
- Where
- 5 sites in Italy
- Volunteers
- 13 people
- Sponsor
- Biogen
Tuberous Sclerosis
A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
This is a single centre, two-arm, individually randomised, Phase II, double- blind, placebo-controlled trial of RAD001 (Everolimus) versus placebo in the treatment of neurocognitive problems in patients with tuberous sclerosis…
- Trial name
- TRON (NCT01954693)
- Testing
- Everolimus (RAD001)
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Cardiff University
Multiple Sclerosis, Neuromyelitis Optica
The Italian Multiple Sclerosis and Related Disorders Register
The Italian Multiple Sclerosis and Related Disorders Register (Registro Italiano Sclerosi Multipla e Patologie Correlate - RISM) is an observational cohort study that aims to create an organised multicentre structure to collect…
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Diseases of the Central Nervous System, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- RISM (NCT07636876)
- Where
- Italy
- Volunteers
- 96,000 people
- Sponsor
- Fondazione Italiana Sclerosi Multipla
Epilepsy, Dravet Syndrome
Turmeric as Treatment in Epilepsy
This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis
- Trial name
- NCT03254680
- Testing
- Turmeric
- Where
- United States
- Sponsor
- NYU Langone Health
Tuberous Sclerosis Complex, Epilepsy
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
This phase I/II clinical trial is an open-label clinical trial design to verify safety and dosing for TAVT-18 (sirolimus) powder for oral solution in TSC infants (N=5).
- Trial name
- STOP2 (NCT04595513)
- Testing
- TAVT-18 (sirolimus)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Multiple Sclerosis, Spasticity, Muscle
" Treating MS Patients With Lower Extremity Spasticity Using Dysport"
The purpose of this study is to determine whether Dysport® (abobotulinumtoxinA) injections for lower extremity spasticity showed a significant reduction of lower extremity spasticity after being injected with Dysport®…
- Trial name
- NCT03585569
- Testing
- Abobotulinumtoxin A
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurology Center of New England P.C.
Multiple Sclerosis, B-Cell Deficiency
B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment
The overall aim of the study is to gain knowledge about consequences for the child´s humoral immunosystem in mothers with multiple sclerosis and due to their immunomodulating treatments.
- Conditions
- Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult, Immunosuppression
- Trial name
- NCT06711354
- Testing
- Anti-CD20 Monoclonal Antibody
- Volunteers
- 111 people
- Sponsor
- Region Stockholm
Multiple Sclerosis, Relapsing Remitting
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is…
- Trial name
- NCT02247310
- Testing
- Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT
- Where
- 11 sites in Austria, Belgium and 9 more
- Volunteers
- 498 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
This open-label, rater-blinded extension study enrolled participants who had relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab (CAMMS223…
- Trial name
- NCT00930553
- Testing
- alemtuzumab
- Where
- 176 sites in United States, Argentina and 21 more
- Volunteers
- 1,314 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing-Remitting Multiple Sclerosis
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and…
- Trial name
- CONNECT (NCT02283853)
- Testing
- dimethyl fumarate, Interferon β-1a
- Where
- 62 sites in United States, Belgium and 16 more
- Volunteers
- 156 people
- Sponsor
- Biogen
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness
The purpose of the study is to determine whether treadmill training is safe and beneficial in patients with walking difficulty because of multiple sclerosis.
- Trial name
- NCT00334100
- Testing
- Exercise
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Pediatric Multiple Sclerosis
Exercise Training in Pediatric-Onset Multiple Sclerosis Patients
Multiple sclerosis is one of the leading causes of disability in young adults. It is known that patients with pediatric onset multiple sclerosis (POMS) experience their first demyelinating attack before the age of 18.
- Trial name
- NCT04660227
- Testing
- Exercise Trainning, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Istanbul University - Cerrahpasa
Type 1 Diabetes Mellitus, Multiple Sclerosis
T and B Cell Responses in Autoimmune Diseases
The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.
- Conditions
- Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease
- Trial name
- SRA01 (NCT01947036)
- Where
- 6 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis
In the present study, we, the investigators at Sheba Medical Center, intend to evaluate T cell vaccination (TCV) in patients with probable multiple sclerosis (MS) within up to 3 months after the first clinical attack.
- Trial name
- NCT00228228
- Testing
- T cell vaccination
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center